Trial Profile
A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2021
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors Jazz Pharmaceuticals Inc
- 20 Jul 2021 Status changed from recruiting to completed.
- 23 Apr 2021 Planned End Date changed from 1 Mar 2021 to 1 Dec 2021.
- 23 Apr 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Jul 2021.